Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 3049 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Ascend GCTx–Ajinomoto: investment, 202305c financing round Series A incl co-investor Ajinomoto Co Inc 2023-05-09
Ascend GCTx–Carlyle: investment, 202305c financing round Series A incl co-lead investor Abingworth 2023-05-09
Ascend GCTx–Cathay Capital: investment, 202305c financing round Series A incl co-investor Cathay Health 2023-05-09
Ascend GCTx–DCVC: investment, 202305c financing round Series A incl co-investor DCVC Bio 2023-05-09
Ascend GCTx–Deerfield: investment, 202305c financing round Series A incl co-investor Deerfield Management 2023-05-09
Ascend GCTx–Digitalis Ventures: investment, 202305c financing round Series A incl co-investor Digitalis Ventures 2023-05-09
Ascend GCTx–Petrichor Healthcare: investment, 202305c financing round Series A incl co-lead investor Petrichor 2023-05-09
Ascend GCTx–Ramarketing: public relations, 202305 service existent Ramarketing is media contact 2023-05-09
Ascend GCTx–SEVERAL: investment, 202305c financing round Series A bringing total raised to $132.5m led by Abingworth + Petrichor 2023-05-09
Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth 2023-05-09
Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ 2023-05-04
Evommune–SEVERAL: investment, 202304 financing round Series B $50m co-led by Arix Bioscience + EQT Life Sciences + SymBiosis 2023-04-26
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd 2023-04-25
Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m 2023-04-19
Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI 2023-04-19
Bellus Health–GSK: investment, 202304–202306 acquisition US$2b in cash at US$14.75/share by GSK 2023-04-18
Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures 2023-04-18
Zetta Genomics–Nina Capital: investment, 202304 2nd seed financing round totalling £1.9m incl existing + lead investor Nina Capital 2023-04-18
Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital 2023-04-18
Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise 2023-04-18
Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV 2023-04-17
Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC 2023-04-17
Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion 2023-04-17
Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv 2023-04-17
Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures 2023-04-17
Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners 2023-04-17
Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences 2023-04-17
Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv 2023-04-17
Mérieux–Oxford Nanopore: nanopore technology, 202304– collab strategic exploring nanopore sequencing for infectious disease diagnostics bioMérieux 2023-04-14
Alentis Therapeutics–Schroders: investment, 202304 financing round Series C totalling $105m incl existing + co-investor Schroders Capital 2023-04-13
Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital 2023-04-13
AMSilk–Optimum Strategic Communications: public relations, 202304 service existent by Optimum 2023-04-04
Biocartis–APIS Assay Technologies: molecular diagnostics, 202304– collab developm + commerc APIS Breast Cancer Subtyping assay on Idylla platform 2023-04-04
Mosaic Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling $28m incl investor CIC 2023-04-04
Mosaic Therapeutics–SEVERAL: investment, 202304 financing round Series A $28m from Syncona + Cambridge Innovation Capital 2023-04-04
Mosaic Therapeutics–Syncona: investment, 202304 financing round Series A totalling $28m incl investor Syncona Investment Management Ltd 2023-04-04
Endpoints–Nikkei: investment, 202304 acquisition of majority share by The Financial Times 2023-04-03
Novartis–Bicycle Therapeutics: Bicycle technology, 202303– strategic collab $50m upfront + $1.7b milestones for targeted radiopharmaceuticals 2023-03-28
SR One–SEVERAL: investment, 202303 closing of SR One Fund II at $600m 2023-03-27
Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi 2023-03-16
Synthego–Arctoris: drug discovery services, 202303– collab co-marketing Arctoris is partner of new drug discovery services network of Synthego 2023-03-16
Teitur Trophics–Optimum Strategic Communications: public relations, 202303 service existent by Optimum 2023-03-14
UCB–Cancer Research UK: antibody cancer drugs, 202303– collab clinical development of UCB6114 + UCB4594 2023-03-09
AstraZeneca–Personalis: precision oncology, 202303– collab continuation use of NeXT Personal assay for clinical reserach + drug development 2023-03-07
Antiverse–SEVERAL: investment, 202303 financing round $3m from existing + new investors 2023-03-01
Five Alarm Bio–Acceleris: investment, 202302 seed financing round totalling >£500k incl angel investors with support from KPMG Acceleris 2023-02-27
Five Alarm Bio–Cambridge Angels: investment, 202302 seed financing round totalling >£500k incl investor Cambridge Angels 2023-02-27
Five Alarm Bio–Meltwind: investment, 202302 seed financing round totalling >£500k incl investor Meltwind 2023-02-27
Five Alarm Bio–o2h: investment, 202302 seed financing round totalling >£500k incl investor o2h Ventures 2023-02-27
Five Alarm Bio–SEVERAL: investment, 202302 seed financing round >£500k 2023-02-27
Five Alarm Bio–SyndicateRoom: investment, 202302 seed financing round totalling >£500k incl investor SyndicateRoom 2023-02-27
Five Alarm Bio–Zyme Communications: public relations, 202302 service existent by Zyme 2023-02-27
eXmoor Pharma–Image Box: public relations, 202302 service existent by IB Communications 2023-02-22
Imophoron–eXmoor Pharma: ADDomer vaccine platform, 202302– collab developm of scalable + commercializable manufacturing platform for ADDomer 2023-02-22
Lift BioSciences–Consilium: public relations, 202302 service existent by Consilium Strategic Communications 2023-02-16
Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM 2023-02-16
Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) 2023-02-15
Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma 2023-02-15
Maxion Therapeutics–BGF: investment, 202302 financing round Series A totalling £13m incl co-investor BGF 2023-02-15
Maxion Therapeutics–LifeArc: investment, 202302 financing round Series A totalling £13m incl lead investor LifeArc Ventures 2023-02-15
Maxion Therapeutics–Monograph Capital: investment, 202302 financing round Series A totalling £13m incl co-investor Monograph Capital 2023-02-15
Maxion Therapeutics–SEVERAL: investment, 202302 financing round Series A £13m led by LifeArc Ventures 2023-02-15
Cerevance–SEVERAL: investment, 202302 financing round Series B extension $51m bringing total Series B to $116m 2023-02-13
Cydar–SEVERAL: investment, 202302 financing round Series A £9.3m led by Pembroke VCT + Downing Healthcare Ventures 2023-02-13
Freeline Therapeutics–Ascend GCTx: investment, 202302 acquisition of Freeline Therapeutics GmbH for $25m by Ascend GCTx Ltd 2023-02-10
HEL Group–Zyme Communications: public relations, 202302 service existent by Zyme 2023-02-08
Evonetix–Cambridge Consultants: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Cambridge Consultants 2023-02-07
Evonetix–Civilization Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Civilization Ventures 2023-02-07
Evonetix–DCVC: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor DCVC 2023-02-07
Evonetix–Foresite Capital: investment, 202302 financing round Series B extension totalling £20m incl existing + lead investor Foresite Capital 2023-02-07
Evonetix–Molten Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Molten Ventures 2023-02-07
Evonetix–Morningside: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Morningside 2023-02-07
Evonetix–Providence Investment: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Providence 2023-02-07
Evonetix–SEVERAL: investment, 202302 financing round Series B extension £20m bringing total Series B to £43m 2023-02-07
Sense Biodetection–Sherlock Biosciences: investment, 202302 acquisition €na of Sense Biodetection by Sherlock Biosciences 2023-02-01
AstraZeneca–Capitainer: sample extraction, 202301– collab research using CapitainerCF self-sampling for clinical research with AZ R&D Gothenbur 2023-01-30
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-19
Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer 2023-01-18
Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-17
InstaDeep–BioNTech: investment, 202301–202307 acquisition of all remaining InstaDeep shares for £362m upfront in cash + shares plus £200m milestones 2023-01-10
CinCor Pharma–AstraZeneca: investment, 202301–202302 acquisition cash tender offer upfront $1.3b ($26/share) + up to $500m CVR at $10/share 2023-01-09
Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea 2023-01-09
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO 2023-01-09
Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED 2023-01-08
Amolyt Pharma–Intermediate Capital Group: investment, 202301 financing round Series C totalling €130m incl co-lead investor ICG 2023-01-06
Amolyt Pharma–SEVERAL: investment, 202301 financing round Series C €130m led by Sofinnova Partners + co-lead by ICG 2023-01-06
Amolyt Pharma–Tekla Capital: investment, 202301 financing round Series C totalling €130m incl new + co-investor Tekla Capital Investment LLC 2023-01-06
Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners 2023-01-05
Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute 2023-01-05
Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners 2023-01-05
Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP 2023-01-05
Mysthera Therapeutics–Forty51 Ventures: investment, 202308 seed financing $3.5m from Forty51 Ventures announced 2023-01-01
Mysthera Therapeutics–Inflection Biosciences: PAM kinase inhibitors, 2023– license to Mysthera from Inflection 2023-01-01
Stablepharma–CrowdCube: investment, 202212 two-part financing round Series A totalling £5.2m incl co-investor CrowdCube 2022-12-23
Stablepharma–Hamilton Portfolio: investment, 202212 two-part financing round Series A totalling £5.2m incl co-lead investor Hamilton Portfolio 2022-12-23
Stablepharma–Oval Investments: investment, 202212 two-part financing round Series A totalling £5.2m incl co-lead investor Oval Investments 2022-12-23
Stablepharma–SEVERAL: investment, 202212 two-part financing round Series A £5.2m led by Hamilton Portfolio + Oval Investments 2022-12-23
Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED 2022-12-22
Inceptor Bio–Ori Biotech: CAGT manufacturing technology, 202212– collab early access to Ori Biotech’s fully automated CGT manufacturing platform 2022-12-15
Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs 2022-12-14
next pagenext page 1 2 3 4 ... 29 30 31  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top